Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Other Operating Expenses (2017 - 2025)

Autolus Therapeutics' Other Operating Expenses history spans 6 years, with the latest figure at $25.3 million for Q4 2025.

  • For Q4 2025, Other Operating Expenses changed N/A year-over-year to $25.3 million; the TTM value through Dec 2025 reached $25.3 million, up 11456.05%, while the annual FY2025 figure was $96.4 million, 43314.8% up from the prior year.
  • Other Operating Expenses reached $25.3 million in Q4 2025 per AUTL's latest filing, up from -$3000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $25.3 million in Q4 2025 to a low of -$3.8 million in Q1 2023.
  • Average Other Operating Expenses over 4 years is $3.5 million, with a median of -$123000.0 recorded in 2023.